Homocysteine-Lowering Vitamin B Treatment Decreases Cardiovascular Events in Hemodialysis Patients
The DOI matches its Crossref record.
Abstract
Background: Dialysis patients have higher cardiovascular events rate than patients with normal renal function. Hyperhomocysteinemia, a risk factor for cardiovascular disease, is frequently detected in dialysis patients. Vitamin B supplementation lowers hyperhomocysteinemia, but it is unknown whether it reduces cardiovascular events rate. We planned a long-term study to analyze the effects of homocysteine-lowering vitamin B therapy on cardiovascular disease in hemodialysis patients. Methods: We performed a single center open prospective trial. Patients, just on folate therapy at enrolment, were left out from randomization and maintained folate therapy according to study’s protocol (group A). Patients, untreated with folic acid at recruitment, were randomly assigned to other 2 groups: patients submitted to folate supplementation according to study’s protocol (group B), and untreated ones (group C). We instructed patients to take 5 mg oral daily folic acid or 5 mg every other day whether serum folate levels were up the normal high limit. We measured homocysteine, folate and vitamin B 12 plasma levels at baseline and every 4 months. We chose the appearance of fatal and nonfatal cardiovascular events as end-points. Results: We analyzed data of 114 patients for a median follow-up time of 871 days. Stepwise regression analysis demonstrated that baseline homocysteine levels were related to folate (coefficient: –1.02; F: 64.5), creatinine (coefficient: 0.98; F: 11.3), and C reactive protein (coefficient: –0.64; F: 4.3). Patients ended the study for the following reasons: cardiovascular morbidity (n = 44), death (n = 25), renal transplant (n = 9), moved away (n = 4). Cardiovascular events occurred in 58 of 114 patients (51%), in 26 of 63 (41%) treated patients (both group A and group B) and in 32 of 51 (63%; χ 2 = 6.0; p = 0.05) untreated patients (group C). Kaplan-Meier survival analysis showed that cardiovascular events were less frequent in treated patients with low homocysteine levels (χ 2 24.1; p < 0.0001). Cox regression analysis showed that cardiovascular events were explained by homocysteine, dialysis vintage, past cardiovascular accidents, and age. We noticed not only lower homocysteine levels, but also higher protein catabolic rate values in events-free patients as compared with patients with nonfatal cardiovascular events. After having divided patients into 4 subgroups according to high and low, split at median, Hcy and protein catabolic rate values, we observed in Kaplan-Meier survival curves for cardiovascular events by these subgroups that patients with low Hcy and high protein catabolic rate values showed a significant lower hazard rate than patients with high Hcy and low protein catabolic rate levels (χ 2 = 21.7; p< 0.0001). Conclusions: This trial shows for the first time that homocysteine-lowering folate therapy decreases cardiovascular events in dialysis patients. It is necessary to perform large prospective studies to confirm our results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Efficacy of folic acid supplementation in stroke prevention: a meta-analysis
Wang, X., Qin, X., Demirtas, H., Li, J., Mao, G., Huo, Y., Sun, N., Liu, L., & Xu, X. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60854-x · Cited by 589
Bazzano, L. A., Reynolds, K., Holder, K. N., & He, J. (2006) · JAMA · doi:10.1001/jama.296.22.2720 · Cited by 426
Holmes, M. V., Newcombe, P., Hubacek, J. A., Sofat, R., Ricketts, S. L., Cooper, J., Breteler, M. M., Bautista, L. E., Sharma, P., Whittaker, J. C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60872-6 · Cited by 331
Li, Y., Huang, T., Zheng, Y., Muka, T., Troup, J., & Hu, F. B. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003768 · Cited by 265
The Role of Homocysteine‐Lowering B‐Vitamins in the Primary Prevention of Cardiovascular Disease
Debreceni, B., & Debreceni, L. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12064 · Cited by 116
Midlife homocysteine and late-life dementia in women. A prospective population study
Zylberstein, D. E., Lissner, L., Björkelund, C., Mehlig, K., Thelle, D. S., Gustafson, D., Östling, S., Waern, M., Guo, X., & Skoog, I. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.024 · Cited by 76
Metadata
- Authors
- Righetti, M., Serbelloni, P., Milani, S., & Ferrario, G.
- Venue
- Blood Purification
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 24
- Issue
- 4
- Pages
- 379-386
- ISSN
- 0253-5068 (ISSN-L)
- 1421-9735
- OpenAlex
- W2061790801
- Cited by
- 115
- References
- 0
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.